Alfredo Ponce-de-Leon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8445108/publications.pdf

Version: 2024-02-01

121 papers 9,491 citations

33 h-index 89 g-index

129 all docs 129 docs citations

times ranked

129

7646 citing authors

#	Article	IF	CITATIONS
1	Large-scale screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among healthcare workers: Prevalence and risk factors for asymptomatic and pauci-symptomatic carriers, with emphasis on the use of personal protective equipment (PPE). Infection Control and Hospital Epidemiology, 2022, 43, 513-517.	1.8	7
2	Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. Emerging Microbes and Infections, 2022, 11, 50-59.	6.5	12
3	Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID). Journal of General Internal Medicine, 2022, 37, 4-14.	2.6	20
4	Serum Vitamin D Levels Are Associated With Increased COVID-19 Severity and Mortality Independent of Whole-Body and Visceral Adiposity. Frontiers in Nutrition, 2022, 9, 813485.	3.7	16
5	Outbreak of NDM-1-Producing Escherichia coli in a Coronavirus Disease 2019 Intensive Care Unit in a Mexican Tertiary Care Center. Microbiology Spectrum, 2022, 10, e0201521.	3.0	6
6	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, The, 2022, 399, 629-655.	13.7	4,915
7	NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. Internal and Emergency Medicine, 2022, 17, 1355-1362.	2.0	11
8	Surveillance of Antimicrobial Resistance in Hospital Wastewater: Identification of Carbapenemase-Producing Klebsiella spp Antibiotics, 2022, 11, 288.	3.7	8
9	Risk Factors Associated with Failure of Linezolid Therapy in Vancomycin-Resistant <i>Enterococcus faecium</i> Bacteremia: A Retrospective Cohort Study in a Referral Center in Mexico. Microbial Drug Resistance, 2022, 28, 744-749.	2.0	4
10	Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19–Induced Acute Respiratory Distress Syndrome. , 2022, 4, e0668.		9
11	<i>Geotrichum</i> spp: An overlooked and fatal etiologic agent in immunocompromised patients. A case series from a referral center in Mexico. Medical Mycology, 2022, 60, .	0.7	2
12	Tracheal Aspirate Galactomannan Testing in COVID-19-Associated Pulmonary Aspergillosis. Frontiers in Fungal Biology, 2022, 3, .	2.0	1
13	Antimicrobial Resistance Patterns and Clonal Distribution of E. coli, Enterobacter spp. and Acinetobacter spp. Strains Isolated from Two Hospital Wastewater Plants. Antibiotics, 2022, 11, 601.	3.7	5
14	Accuracy of galactomannan testing on tracheal aspirates in COVIDâ€19â€essociated pulmonary aspergillosis. Mycoses, 2021, 64, 364-371.	4.0	44
15	Low Thoracic Skeletal Muscle Area Is Not Associated With Negative Outcomes in Patients With COVID-19. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 413-418.	1.4	28
16	In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. PLoS ONE, 2021, 16, e0245772.	2.5	94
17	Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Research and Care, 2021, 9, e002026.	2.8	46
18	Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet, The, 2021, 397, 499-509.	13.7	119

#	Article	IF	Citations
19	Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. Antibiotics, 2021, 10, 182.	3.7	31
20	Adaptive Metabolic and Inflammatory Responses Identified Using Accelerated Aging Metrics Are Linked to Adverse Outcomes in Severe SARS-CoV-2 Infection. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, e117-e126.	3.6	11
21	Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in COVID-19 patients. Scientific Reports, 2021, 11, 6350.	3.3	91
22	Diagnostic accuracy of antigen detection in urine and molecular assays testing in different clinical samples for the diagnosis of progressive disseminated histoplasmosis in patients living with HIV/AIDS: A prospective multicenter study in Mexico. PLoS Neglected Tropical Diseases, 2021, 15, e0009215.	3.0	25
23	Risk factors and outcomes associated with vancomycin-resistant Enterococcus faecium and ampicillin-resistant Enterococcus faecalis bacteraemia: A 10-year study in a tertiary-care centre in Mexico City. Journal of Global Antimicrobial Resistance, 2021, 24, 198-204.	2.2	15
24	Thoracic actinomycetoma: a retrospective clinical-epidemiological study of 64 cases. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 337-339.	1.8	O
25	Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology, 2021, 11, 640707.	3.9	2
26	Sepsis outbreak associated with use of contaminated propofol in an outpatient procedure clinic. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 304-305.	0.3	O
27	Sepsis outbreak associated with use of contaminated propofol in an outpatient procedure clinic. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 304-305.	0.5	2
28	Redefining COVID-19 Severity and Prognosis: The Role of Clinical and Immunobiotypes. Frontiers in Immunology, 2021, 12, 689966.	4.8	19
29	Isolation of Rhizopus microsporus and Lichtheimia corymbifera from tracheal aspirates of two immunocompetent critically ill patients with COVID-19. Medical Mycology Case Reports, 2021, 33, 32-37.	1.3	4
30	COVID-19: What�s Next?. Revista De Investigacion Clinica, 2021, 73, 329-334.	0.4	1
31	Genetic diversity and primary drug resistance transmission in Mycobacterium tuberculosis in southern Mexico. Infection, Genetics and Evolution, 2021, 93, 104994.	2.3	8
32	Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients. American Journal of Infection Control, 2021, 49, 966-968.	2.3	30
33	Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center. Revista De Investigacion Clinica, 2021, , .	0.4	3
34	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	10.7	119
35	Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network. Microbial Drug Resistance, 2021, , .	2.0	17
36	New opportunities in tuberculosis prevention: implications for people living with HIV. Journal of the International AIDS Society, 2020, 23, e25438.	3.0	20

#	Article	IF	CITATIONS
37	B Cell Subsets as Severity-Associated Signatures in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 611004.	4.8	101
38	The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis. Journal of Hospital Infection, 2020, 105, 757-765.	2.9	3
39	High prevalence of MDR gram-negative bacteria in feces of healthy blood donors in Mexico. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1439-1444.	2.9	1
40	Nontuberculous mycobacterial infection in a tertiary care center in Mexico, 2001–2017. Brazilian Journal of Infectious Diseases, 2020, 24, 213-220.	0.6	11
41	The Evolution of Antimicrobial Resistance in Mexico During the Last Decade: Results from the INVIFAR Group. Microbial Drug Resistance, 2020, 26, 1372-1382.	2.0	18
42	In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. Journal of Antimicrobial Chemotherapy, 2020, 75, 1859-1873.	3.0	11
43	Latent Tuberculosis in Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Strategies to Prevent Disease Activation in an Endemic Population. Biology of Blood and Marrow Transplantation, 2020, 26, 1350-1354.	2.0	9
44	Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis. BMC Infectious Diseases, 2020, 20, 250.	2.9	12
45	Validation and repurposing of the MSL-COVID-19 score for prediction of severe COVID-19 using simple clinical predictors in a triage setting: The Nutri-CoV score. PLoS ONE, 2020, 15, e0244051.	2.5	22
46	Clinical and Epidemiological Characteristics of Patients Diagnosed with COVID-19 in a Tertiary Care Center in Mexico City: A Prospective Cohort Study. Revista De Investigacion Clinica, 2020, 72, 165-177.	0.4	63
47	Wuhan: Back to the Future and the Return of Coronaviruses. Revista De Investigacion Clinica, 2020, 72, 5-7.	0.4	1
48	Title is missing!. , 2020, 15, e0244051.		0
49	Title is missing!. , 2020, 15, e0244051.		0
50	Title is missing!. , 2020, 15, e0244051.		0
51	Title is missing!. , 2020, 15, e0244051.		0
52	AUTHOR'S REPLY. Revista De Investigacion Clinica, 2020, 72, 251.	0.4	0
53	Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases. Blood Research, 2019, 54, 120-124.	1.3	5
54	Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis. Frontiers in Microbiology, 2019, 10, 2097.	3.5	31

#	Article	IF	CITATIONS
55	Vaccine-derived varicella zoster infection in a kidney transplant recipient after zoster vaccine live administration. Vaccine, 2019, 37, 3576-3579.	3.8	11
56	Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients. European Respiratory Journal, 2019, 54, 1800353.	6.7	22
57	<i>Mycobacterium obuense</i> Bacteremia in a Patient with Pneumonia. Emerging Infectious Diseases, 2019, 25, 1015-1016.	4.3	4
58	Vancomycin-resistant Enterococcus faecium sensitivity to isopropyl alcohol before and after implementing alcohol hand rubbing in a hospital. American Journal of Infection Control, 2019, 47, e27-e29.	2.3	4
59	A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. PLoS ONE, 2019, 14, e0209865.	2.5	37
60	Azole resistance and cyp51A mutation screening in Aspergillus fumigatus in Mexico. Journal of Antimicrobial Chemotherapy, 2019, 74, 2047-2050.	3.0	15
61	False-positive results in the galactomannan Plateliaâ, Aspergillus assay with generic piperacillin/tazobactam. Revista Iberoamericana De Micologia, 2019, 36, 51-52.	0.9	6
62	Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid. Journal of Immunology Research, 2019, 2019, 1-13.	2.2	16
63	Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City. Clinical Rheumatology, 2018, 37, 2095-2102.	2.2	16
64	Potential Effect of Statins on Mycobacterium tuberculosis Infection. Journal of Immunology Research, 2018, 2018, 1-14.	2.2	15
65	Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center. Brazilian Journal of Infectious Diseases, 2018, 22, 387-391.	0.6	1
66	Diagnostic accuracy cohort study and clinical value of the Histoplasma urine antigen (ALPHA) Tj ETQq0 0 0 rgBT PLoS Neglected Tropical Diseases, 2018, 12, e0006872.	Overlock 3.0	10 Tf 50 307 21
67	Chronic pulmonary aspergillosis after pulmonary tuberculosis. Cmaj, 2018, 190, E1171-E1171.	2.0	1
68	Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). PLoS ONE, 2018, 13, e0198621.	2.5	30
69	Raising concerns about the Sepsis-3 definitions. World Journal of Emergency Surgery, 2018, 13, 6.	5.0	81
70	Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study. PLoS ONE, 2018, 13, e0198212.	2.5	12
71	The Systemic Lupus Erythematosus Infection Predictive Index (LIPI): A Clinical-Immunological Tool to Predict Infections in Lupus Patients. Frontiers in Immunology, 2018, 9, 3144.	4.8	23
72	Genotyping and spatial analysis of pulmonary tuberculosis and diabetes cases in the state of Veracruz, Mexico. PLoS ONE, 2018, 13, e0193911.	2.5	9

#	Article	IF	Citations
73	Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center. International Journal of Infectious Diseases, 2017, 65, 44-49.	3.3	20
74	Identification and susceptibility testing of Candida spp . directly from yeast-positive blood cultures with Vitek 2. Diagnostic Microbiology and Infectious Disease, 2017, 89, 202-204.	1.8	1
7 5	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
76	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardshipâ€"results from an international cross-sectional survey. World Journal of Emergency Surgery, 2017, 12, 34.	5.0	47
77	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. BMC Infectious Diseases, 2017, 17, 753.	2.9	15
78	Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0184675.	2.5	15
79	Clinical and Epidemiological Description of Diarrheal Episodes Caused by Clostridium difficile RT027 in Mexico. Open Forum Infectious Diseases, 2016, 3, .	0.9	O
80	Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case–control-control study. Diagnostic Microbiology and Infectious Disease, 2016, 86, 243-248.	1.8	8
81	Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010. PLoS ONE, 2016, 11, e0168955.	2.5	23
82	Seroprevalence of brucellosis among dairy farm workers in Mexico. Salud Publica De Mexico, 2016, 58, 366-370.	0.4	1
83	Trends of Mycobacterium bovis Isolation and First-Line Anti-tuberculosis Drug Susceptibility Profile: A Fifteen-Year Laboratory-Based Surveillance. PLoS Neglected Tropical Diseases, 2015, 9, e0004124.	3.0	34
84	Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000–2012. PLoS ONE, 2015, 10, e0129312.	2.5	41
85	Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital. PLoS ONE, 2015, 10, e0139883.	2.5	59
86	Outbreak Caused by Enterobacteriaceae Harboring NDM-1 Metallo-Î ² -Lactamase Carried in an IncFII Plasmid in a Tertiary Care Hospital in Mexico City. Antimicrobial Agents and Chemotherapy, 2015, 59, 7080-7083.	3.2	56
87	Impact of ertapenem on antimicrobial resistance in a sentinel group of Gram-negative bacilli: a 6 year antimicrobial resistance surveillance study. Journal of Antimicrobial Chemotherapy, 2015, 70, 914-921.	3.0	8
88	Surveillance of Candida spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. PLoS ONE, 2014, 9, e97325.	2.5	30
89	Results of the Implementation of a Pilot Model for the Bidirectional Screening and Joint Management of Patients with Pulmonary Tuberculosis and Diabetes Mellitus in Mexico. PLoS ONE, 2014, 9, e106961.	2.5	28
90	Diagnosis and Treatment of Non-European Fungal Infections. Current Fungal Infection Reports, 2014, 8, 343-352.	2.6	2

#	Article	IF	CITATIONS
91	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116
92	Risk Factors for Drug-resistant Bloodstream Infections in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 1311-1316.	2.0	15
93	Sir3 Polymorphisms in Candida glabrata Clinical Isolates. Mycopathologia, 2013, 175, 207-219.	3.1	11
94	Impact of cigarette smoking on rates and clinical prognosis of pulmonary tuberculosis in Southern Mexico. Journal of Infection, 2013, 66, 303-312.	3.3	20
95	Prevalence of Latent and Active Tuberculosis among Dairy Farm Workers Exposed to Cattle Infected by Mycobacterium bovis. PLoS Neglected Tropical Diseases, 2013, 7, e2177.	3.0	57
96	Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax, 2013, 68, 214-220.	5.6	221
97	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
98	Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. Age and Ageing, 2012, 41, 488-495.	1.6	58
99	Epidemiology of Invasive Fungal Infections in Latin America. Current Fungal Infection Reports, 2012, 6, 23-34.	2.6	85
100	Importance of differentiating Mycobaterium bovis in tuberculous meningitis. Neurology International, 2011, 3, 9.	2.8	10
101	Concordance Between Two Enzyme Immunoassays for the Detection of Clostridium difficile Toxins. Archives of Medical Research, 2010, 41, 92-96.	3. 3	6
102	Virulence, immunopathology and transmissibility of selected strains of <i>Mycobacterium tuberculosis </i> i>in a murine model. Immunology, 2009, 128, 123-133.	4.4	75
103	Molecular Analysis of Mycobacterium tuberculosis Strains with an Intact pks15/1 Gene in a Rural Community of Mexico. Archives of Medical Research, 2008, 39, 809-814.	3.3	13
104	Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum \hat{l}^2 -lactamase-producing Klebsiella pneumoniae. International Journal of Infectious Diseases, 2008, 12, 653-659.	3.3	49
105	Unique Gene Expression Profiles in Infants Vaccinated with Different Strains of Mycobacterium bovis Bacille Calmette-Guelrin. Infection and Immunity, 2007, 75, 3658-3664.	2.2	52
106	Vancomycin-resistant Enterococci, Mexico City. Emerging Infectious Diseases, 2007, 13, 798-799.	4.3	18
107	Global Phylogeny of Mycobacterium tuberculosis Based on Single Nucleotide Polymorphism (SNP) Analysis: Insights into Tuberculosis Evolution, Phylogenetic Accuracy of Other DNA Fingerprinting Systems, and Recommendations for a Minimal Standard SNP Set. Journal of Bacteriology, 2006, 188, 759-772.	2.2	381
108	Is tuberculin skin testing useful to diagnose latent tuberculosis in BCG-vaccinated children?. International Journal of Epidemiology, 2006, 35, 1447-1454.	1.9	17

#	Article	IF	CITATIONS
109	Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 2640-2649.	3.2	364
110	Changes in the geographical distribution of tuberculosis patients in Veracruz, Mexico, after reinforcement of a tuberculosis control programme. Tropical Medicine and International Health, 2005, 10, 305-311.	2.3	16
111	Role of <i>embB</i> Codon 306 Mutations in <i>Mycobacterium tuberculosis</i> Revisited: a Novel Association with Broad Drug Resistance and IS <i>6110</i> Clustering Rather than Ethambutol Resistance. Antimicrobial Agents and Chemotherapy, 2005, 49, 3794-3802.	3.2	103
112	Does DOTS work in populations with drug-resistant tuberculosis?. Lancet, The, 2005, 365, 1239-1245.	13.7	78
113	Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates from India and Mexico by a Molecular Beacon Assay. Journal of Clinical Microbiology, 2004, 42, 5512-5516.	3.9	38
114	Tuberculosis and Diabetes in Southern Mexico. Diabetes Care, 2004, 27, 1584-1590.	8.6	182
115	Nested Polymerase Chain Reaction for Mycobacterium tuberculosis DNA Detection in Aqueous and Vitreous of Patients with Uveitis. Archives of Medical Research, 2003, 34, 116-119.	3.3	63
116	Rapid identification and susceptibility testing of Mycobacterium tuberculosis from MGIT cultures with luciferase reporter mycobacteriophages. Journal of Medical Microbiology, 2003, 52, 557-561.	1.8	52
117	Tuberculosis-Related Deaths within a Well-Functioning DOTS Control Program. Emerging Infectious Diseases, 2002, 8, 1327-1333.	4.3	40
118	Clinical Consequences and Transmissibility of Drug-Resistant Tuberculosis in Southern Mexico. Archives of Internal Medicine, 2000, 160, 630-6.	3.8	87
119	Cefepime versus ceftazidime for the treatment of serious bacterial infections. Diagnostic Microbiology and Infectious Disease, 1999, 35, 263-268.	1.8	3
120	Investigaci \tilde{A}^3 n sobre epidemiolog \tilde{A} a convencional y molecular de tuberculosis en Orizaba, Veracruz, 1995-2008. Salud Publica De Mexico, 0, 51, .	0.4	2
121	Integrating tuberculosis research with public health infrastructure: Lessons on community engagement from Orizaba, Mexico. Gates Open Research, 0, 4, 11.	1.1	1